Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation: A prospective study of 22 patients with hematologic malignancies

Roberto Rodriguez, P. Parker, A. Nademanee, D. Smith, M. R. O'Donnell, A. Stein, D. S. Snyder, H. C. Fung, A. Y. Krishnan, L. Popplewell, S. Cohen, G. Somlo, M. Angelopoulou, Z. Al-Kadhimi, P. M. Falk, R. Spielberger, N. Kogut, F. Sahebi, D. Senitzer, M. SlovakJ. Schriber, S. J. Forman

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

In an attempt to decrease toxicity in high-risk patients undergoing unrelated donor hematopoietic stem cell transplantation (URD HSCT), we tested a combination of cyclosporine (CSP) and mycophenolate mofetil (MMF) as graft-versus-host disease (GVHD) prophylaxis with the reduced-intensity conditioning regimen fludarabine/melphalan (Flu/Mel). A total of 22 adult patients with advanced myeloid (n = 15) and lymphoid (n = 7) malignancies were treated. All patients received Flu 25 mg/m2 for 5 days and Mel 140 mg/m2, with CSP 3 mg/kg daily and MMF 15 mg/kg three times a day. The median age was 49 years (range 18-66). Durable engraftment was seen in all but one patient with myelofibrosis. The 1-year nonrelapse mortality was 32%, 27% from GVHD. The cumulative incidence of acute GVHD grade 2-4 and 3-4 was 63 and 41%, respectively. With a median follow-up of 18 months, the disease-free survival (DFS) and overall survival (OS) are 55 and 59%, respectively. For patients with AML and MDS (n = 14), the DFS and OS is 71%. For patients undergoing a second transplant (n = 14), the DFS and OS is 57%. In conclusion, this regimen is associated with acceptable toxicity but high rates of GVHD in high-risk patients undergoing URD HSCT. Encouraging disease control for patients with advanced myeloid malignancies was observed.

Original languageEnglish (US)
Pages (from-to)1123-1129
Number of pages7
JournalBone marrow transplantation
Volume33
Issue number11
DOIs
StatePublished - Jun 1 2004

Fingerprint

Mycophenolic Acid
Unrelated Donors
Melphalan
Hematologic Neoplasms
Cyclosporine
Transplantation
Prospective Studies
Graft vs Host Disease
Disease-Free Survival
Hematopoietic Stem Cell Transplantation
Survival
Primary Myelofibrosis
fludarabine
Neoplasms
Transplants
Mortality
Incidence

Keywords

  • Adult
  • Graft-versus-host disease
  • Hematopoietic cell transplantation
  • Reduced-intensity conditioning
  • Unrelated donor

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation : A prospective study of 22 patients with hematologic malignancies. / Rodriguez, Roberto; Parker, P.; Nademanee, A.; Smith, D.; O'Donnell, M. R.; Stein, A.; Snyder, D. S.; Fung, H. C.; Krishnan, A. Y.; Popplewell, L.; Cohen, S.; Somlo, G.; Angelopoulou, M.; Al-Kadhimi, Z.; Falk, P. M.; Spielberger, R.; Kogut, N.; Sahebi, F.; Senitzer, D.; Slovak, M.; Schriber, J.; Forman, S. J.

In: Bone marrow transplantation, Vol. 33, No. 11, 01.06.2004, p. 1123-1129.

Research output: Contribution to journalArticle

Rodriguez, R, Parker, P, Nademanee, A, Smith, D, O'Donnell, MR, Stein, A, Snyder, DS, Fung, HC, Krishnan, AY, Popplewell, L, Cohen, S, Somlo, G, Angelopoulou, M, Al-Kadhimi, Z, Falk, PM, Spielberger, R, Kogut, N, Sahebi, F, Senitzer, D, Slovak, M, Schriber, J & Forman, SJ 2004, 'Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation: A prospective study of 22 patients with hematologic malignancies', Bone marrow transplantation, vol. 33, no. 11, pp. 1123-1129. https://doi.org/10.1038/sj.bmt.1704493
Rodriguez, Roberto ; Parker, P. ; Nademanee, A. ; Smith, D. ; O'Donnell, M. R. ; Stein, A. ; Snyder, D. S. ; Fung, H. C. ; Krishnan, A. Y. ; Popplewell, L. ; Cohen, S. ; Somlo, G. ; Angelopoulou, M. ; Al-Kadhimi, Z. ; Falk, P. M. ; Spielberger, R. ; Kogut, N. ; Sahebi, F. ; Senitzer, D. ; Slovak, M. ; Schriber, J. ; Forman, S. J. / Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation : A prospective study of 22 patients with hematologic malignancies. In: Bone marrow transplantation. 2004 ; Vol. 33, No. 11. pp. 1123-1129.
@article{3589d7940de1403da0294155701f43d4,
title = "Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation: A prospective study of 22 patients with hematologic malignancies",
abstract = "In an attempt to decrease toxicity in high-risk patients undergoing unrelated donor hematopoietic stem cell transplantation (URD HSCT), we tested a combination of cyclosporine (CSP) and mycophenolate mofetil (MMF) as graft-versus-host disease (GVHD) prophylaxis with the reduced-intensity conditioning regimen fludarabine/melphalan (Flu/Mel). A total of 22 adult patients with advanced myeloid (n = 15) and lymphoid (n = 7) malignancies were treated. All patients received Flu 25 mg/m2 for 5 days and Mel 140 mg/m2, with CSP 3 mg/kg daily and MMF 15 mg/kg three times a day. The median age was 49 years (range 18-66). Durable engraftment was seen in all but one patient with myelofibrosis. The 1-year nonrelapse mortality was 32{\%}, 27{\%} from GVHD. The cumulative incidence of acute GVHD grade 2-4 and 3-4 was 63 and 41{\%}, respectively. With a median follow-up of 18 months, the disease-free survival (DFS) and overall survival (OS) are 55 and 59{\%}, respectively. For patients with AML and MDS (n = 14), the DFS and OS is 71{\%}. For patients undergoing a second transplant (n = 14), the DFS and OS is 57{\%}. In conclusion, this regimen is associated with acceptable toxicity but high rates of GVHD in high-risk patients undergoing URD HSCT. Encouraging disease control for patients with advanced myeloid malignancies was observed.",
keywords = "Adult, Graft-versus-host disease, Hematopoietic cell transplantation, Reduced-intensity conditioning, Unrelated donor",
author = "Roberto Rodriguez and P. Parker and A. Nademanee and D. Smith and O'Donnell, {M. R.} and A. Stein and Snyder, {D. S.} and Fung, {H. C.} and Krishnan, {A. Y.} and L. Popplewell and S. Cohen and G. Somlo and M. Angelopoulou and Z. Al-Kadhimi and Falk, {P. M.} and R. Spielberger and N. Kogut and F. Sahebi and D. Senitzer and M. Slovak and J. Schriber and Forman, {S. J.}",
year = "2004",
month = "6",
day = "1",
doi = "10.1038/sj.bmt.1704493",
language = "English (US)",
volume = "33",
pages = "1123--1129",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation

T2 - A prospective study of 22 patients with hematologic malignancies

AU - Rodriguez, Roberto

AU - Parker, P.

AU - Nademanee, A.

AU - Smith, D.

AU - O'Donnell, M. R.

AU - Stein, A.

AU - Snyder, D. S.

AU - Fung, H. C.

AU - Krishnan, A. Y.

AU - Popplewell, L.

AU - Cohen, S.

AU - Somlo, G.

AU - Angelopoulou, M.

AU - Al-Kadhimi, Z.

AU - Falk, P. M.

AU - Spielberger, R.

AU - Kogut, N.

AU - Sahebi, F.

AU - Senitzer, D.

AU - Slovak, M.

AU - Schriber, J.

AU - Forman, S. J.

PY - 2004/6/1

Y1 - 2004/6/1

N2 - In an attempt to decrease toxicity in high-risk patients undergoing unrelated donor hematopoietic stem cell transplantation (URD HSCT), we tested a combination of cyclosporine (CSP) and mycophenolate mofetil (MMF) as graft-versus-host disease (GVHD) prophylaxis with the reduced-intensity conditioning regimen fludarabine/melphalan (Flu/Mel). A total of 22 adult patients with advanced myeloid (n = 15) and lymphoid (n = 7) malignancies were treated. All patients received Flu 25 mg/m2 for 5 days and Mel 140 mg/m2, with CSP 3 mg/kg daily and MMF 15 mg/kg three times a day. The median age was 49 years (range 18-66). Durable engraftment was seen in all but one patient with myelofibrosis. The 1-year nonrelapse mortality was 32%, 27% from GVHD. The cumulative incidence of acute GVHD grade 2-4 and 3-4 was 63 and 41%, respectively. With a median follow-up of 18 months, the disease-free survival (DFS) and overall survival (OS) are 55 and 59%, respectively. For patients with AML and MDS (n = 14), the DFS and OS is 71%. For patients undergoing a second transplant (n = 14), the DFS and OS is 57%. In conclusion, this regimen is associated with acceptable toxicity but high rates of GVHD in high-risk patients undergoing URD HSCT. Encouraging disease control for patients with advanced myeloid malignancies was observed.

AB - In an attempt to decrease toxicity in high-risk patients undergoing unrelated donor hematopoietic stem cell transplantation (URD HSCT), we tested a combination of cyclosporine (CSP) and mycophenolate mofetil (MMF) as graft-versus-host disease (GVHD) prophylaxis with the reduced-intensity conditioning regimen fludarabine/melphalan (Flu/Mel). A total of 22 adult patients with advanced myeloid (n = 15) and lymphoid (n = 7) malignancies were treated. All patients received Flu 25 mg/m2 for 5 days and Mel 140 mg/m2, with CSP 3 mg/kg daily and MMF 15 mg/kg three times a day. The median age was 49 years (range 18-66). Durable engraftment was seen in all but one patient with myelofibrosis. The 1-year nonrelapse mortality was 32%, 27% from GVHD. The cumulative incidence of acute GVHD grade 2-4 and 3-4 was 63 and 41%, respectively. With a median follow-up of 18 months, the disease-free survival (DFS) and overall survival (OS) are 55 and 59%, respectively. For patients with AML and MDS (n = 14), the DFS and OS is 71%. For patients undergoing a second transplant (n = 14), the DFS and OS is 57%. In conclusion, this regimen is associated with acceptable toxicity but high rates of GVHD in high-risk patients undergoing URD HSCT. Encouraging disease control for patients with advanced myeloid malignancies was observed.

KW - Adult

KW - Graft-versus-host disease

KW - Hematopoietic cell transplantation

KW - Reduced-intensity conditioning

KW - Unrelated donor

UR - http://www.scopus.com/inward/record.url?scp=2942718577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942718577&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1704493

DO - 10.1038/sj.bmt.1704493

M3 - Article

C2 - 15064696

AN - SCOPUS:2942718577

VL - 33

SP - 1123

EP - 1129

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 11

ER -